STAAR Surgical Company Reports 6.9% Increase in Q3 Net Sales

By Tamara Parker • Monday, October 20 15:36 • Permanent Link

Staar Surgical Company (NASDAQ: STAA) has announced its preliminary net sales results for the third quarter ended September 26, 2025. The company reported preliminary net sales of $94.7 million, representing a 6.9% increase compared to $88.6 million in the prior year period.

The preliminary net sales included $25.9 million related to the previously disclosed December 2024 ICL shipment, which was subject to extended payment terms and was paid in full during the third quarter of 2025. The year-over-year increase in preliminary net sales was primarily driven by the December China shipment, combined with 7.7% growth in net sales outside China. This growth was partially offset by lower new orders from distributors in China during the third quarter of 2025, attributed to leaner inventory management.

Staar Surgical recognized $1.6 million related to the December 2024 shipment in the second quarter of 2025 and the remaining $25.9 million in the third quarter of 2025, upon receipt of corresponding payment. The company also noted that sales for the nine months ended September 26, 2025, were lower than the prior year period as distributors in China reduced their inventory by approximately $80 million to $85 million instead of purchasing new product from the company. As of September 26, 2025, the company believes its distributors in China maintained owned inventory at approximately six months, aligned to contractual levels.

The financial information provided in the release is unaudited and is subject to adjustment and confirmation as the company completes its quarterly review and finalizes its financial statements to be filed with the company’s quarterly report on Form 10-Q for the quarter ended September 26, 2025.

Staar Surgical, headquartered in Lake Forest, California, is a global leader in implantable phakic intraocular lenses and has been dedicated solely to ophthalmic surgery since 1982. The company's Evo ICL™ product line provides visual freedom through a quick, minimally invasive procedure, and it has sold more than 3 million ICLs in over 75 countries.

The company is set to hold a special meeting of stockholders on October 23, 2025, to vote on the Alcon merger proposal.

For further details on voting shares, stockholders can contact Staar’s proxy solicitor, Innisfree M&A Incorporated. The market has reacted to these announcements by moving the company's shares 3.17% to a price of $25.03. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.